Eli Mordechai, Ph.D.
Chief Executive Officer
Eli Mordechai, Ph.D., is the founder of the privately-held Genesis Global Group (GGG) and Genesis Biotechnology Group (GBG) headquartered in Hamilton, New Jersey. As the Chief Executive Officer, Dr. Mordechai’s forward-thinking leadership inspires and empowers the ongoing discovery and development of innovative scientific products and services that fulfill important clinical needs to enhance the quality of life of patients in the United States and around the world. With visions of executing GBG’s mission of delivering inventive products and services while growing steadily and competitively in the biotechnology marketplace, Dr. Mordechai continues to expand GBG with vertically-integrated business initiatives in mind. Dr. Mordechai’s successes in tactically implementing vertical integration are evidenced by GBG’s collection of operational platforms in laboratory sciences, clinical research, drug discovery, and manufacturing and the comprehensive services, efficiencies, and creativity these collaborative processes yield.
Dr. Mordechai oversees GBG’s day-to-day operations and meets with his senior executive teams on a regular basis to ensure that all the companies of GBG maintain the highest standards of corporate excellence, accountability and transparency. Dr. Mordechai investigates and monitors trends and forecasts in the biotechnology and healthcare industries to manage risk and optimally navigate business development for each of GBG’s enterprises. His focus for GBG’s market expansion involves driving core organic growth, initiating new lines of business, and being an active participant in the merger and acquisition arena. Building executive management teams comprised of industry-leading experts to carry out GBG’s missions and promote its corporate culture of opportunity, honesty, unsurpassed values and professional practices is another of Dr. Mordechai’s priorities as Chief Executive Officer.
Dr. Mordechai received his Bachelors of Science degree in Biochemistry from Rider University in Lawrenceville, New Jersey, and upon graduation he was distinguished with ‘The Biochemistry Departmental Award’. He went on to earn his Ph.D. in Biochemistry from the Department of Biochemistry at Temple University School of Medicine in Philadelphia. At Temple University, Dr. Mordechai was the recipient of ‘The Florence Gloria Freeman Cancer Research Award’. He completed his post-doctoral studies at the Department of Neurobiology at the Barrow Neurological Institute St. Joseph’s Hospital in Phoenix, Arizona. Following the completion of his post-doctoral studies, he served as the Director of Research and Development at the Immunosciences Laboratory in Beverly Hills, California.
Dr. Mordechai scientific research is documented in over 100 peer-reviewed publications and abstracts. He has presented at a vast array scientific meetings and industry conferences, and he has authored over 25 patents. Dr. Mordechai is an Associate Professor at Rowan University Graduate School of Biomedical Sciences, and he also serves as an active member on many academic and scientific boards such as, Rider University Science Advisory Board, Board of Trustee of Rider University, Chemistry/Biochemistry Advisory Board at Burlington County Community College, Dean Development Council at Rowan University (formally UMDNJ), the Scientific Advisory Board of the Hepatitis B Foundation, and the Pennsylvania Biotechnology Center.
As an accomplished scientist, business executive, and leading community figure, Eli Mordechai, Ph.D.’s body of work and stellar reputation epitomize American ingenuity and have earned him several academic, industrial and community awards, including the Ernst & Young ‘Entrepreneur of the Year’ award. He was voted ‘Most 50 Interesting People in Mercer County’, and he received the esteemed Dean Council Award from the University of Medicine and Dentistry in New Jersey. Dr. Mordechai holds a certificate as a Medical Director from the Wadsworth Center New York State Department of Health and from the American Association of Bioanalysts (AAB). His current professional memberships include the American Society of Microbiology, Association for Molecular Pathology, International Society for Infectious Diseases, and the American Association for the Advancement of Medicine.
Martin E. Adelson, Ph.D.
Chief Operating Officer
Corporate Department and Research Department
Dr. Adelson joined the GBG team in 2002. As the Chief Operating Officer, Dr. Adelson leads clinical, development, and discovery research operations in Medical Diagnostic Laboratories (MDL), Venenum Biodesign, and Invivotek with his main focus concentrating on scaling and expanding the existing business infrastructure through both organic growth and corporate acquisition. In addition, Dr. Adelson implements various innovations and re-engineering initiatives, as well as leverages customized technology solutions, to re-calibrate and enhance MDL's workflow while reducing overall business costs.
Prior to his appointment to Chief Operating Officer in 2013, Dr. Adelson held positions within MDL as Director of Research & Development before becoming Vice President of MDL in 2007.
Dr. Adelson received his BS in Biology from The College of New Jersey (formerly Trenton State College) in Ewing, NJ. He earned his Ph.D. in Molecular Biology & Genetics from the Department of Molecular Biology and Genetics/Fels Institute for Molecular Biology and Cancer at Temple University School of Medicine in Philadelphia, PA. He completed his postdoctoral studies in the Department of Microbiology and Molecular Genetics at the University of Medicine and Dentistry of New Jersey. Dr. Adleson was the proud recipient of a competitive Postdoctoral Research Fellowship from the National Institutes of Health, National Lung, and Blood Institute.
Dr. Adelson has presented more than 15 presentations for scientific meetings and conferences, clients, and special events. He is the author of 60 publications and 82 abstracts including:
- Adelson ME, Feola M, Trama JP, Tilton RC, and Mordechai E. (2005). Simultaneous detection of herpes simplex virus types 1 and 2 by real-time PCR and Pyrosequencing. Journal of Clinical Virology, 33(1): 15-34. ’s
Dr. Adelson is an Associate Professor at Rowan University Graduate School of Biomedical Sciences as well as a present Member of the Thomas Jefferson University Biotechnology Program Advisory Committee. He has served on the editorial boards of Diagnostic Microbiology and Infectious Disease and Journal of Clinical Microbiology. He has also served as a guest reviewer for the Journal of Clinical Microbiology, Infection & Immunity, Journal of Applied and Experimental Microbiology, Clinical and Diagnostic Microbiology, Journal of Dermatological Science, Diagnostic Microbiology and Infectious Disease, and Clinical and Vaccine Immunology. He serves as a Scientific Advisory Board member of JBS Science, Inc. at the PA Biotechnology Center and is a founding member of the New Jersey and Pennsylvania BioTech and Life Sciences Leadership Council. Dr. Adelson also holds a certificate as a Medical Director from the Wadsworth Center New York State Department of Health. His current professional memberships include the American Society of Microbiology, International Organization for Mycoplasmology, and Association for Molecular Pathology.
Ben Bandaru, Ph.D., MBA
Director of Corporate Development
Ben joined the GBG team in 2015. As the Director of Corporate Development, he provides leadership for strategy development initiatives by working closely with the CEO and strategic business units to drive all acquisitive growth initiatives for GBG and member companies from initiating to closing and onboarding the transaction. Through collaboration with private equity and investment banks, Ben develops and structures deals, organizes and manages the buy-side, sell-side, intellectual property out-licensing, and joint venture projects to originate new businesses and develop existing relationships.
Prior to GBG, Ben was the Vice President of US Operations, Strategic Programs, and Business Development at iMEDGlobal Corporation. Additionally, Ben held a number of positions in Pfizer Inc., where he served in and led teams in Healthcare Informatics, Acquisition Collaboration and Divestitures, Global R&D, and Global Manufacturing before becoming the Product Development Lead in the Integrated Health Business Unit. During his time with Pfizer, he was the proud recipient of the Pfizer Innovation Award.
Ben received his MBA with a concentration in Strategy from Rensselaer Polytechnic Institute. He earned his Ph.D. in Biochemistry from Wayne State University. Ben also holds a certificate as a Project Management Professional (PMP) from the Project Management Institute.
Ben’s list of publications includes:
- Bandaru, B., Jaishree, G., and and Bhagwat, A. S., 1996, Overproduction of DNA Cytosine Methyltransferases causes Methylation and C to T Mutations at Non-canonical sites, Journal of Biological Chemistry, Vol. 271, No. 13, Issue of March 29, pp. 7851–7859, 1996.
- Bandaru, B., Wyszynski, M., and Bhagwat, A. S., 1995, HpaII methyltransferase is mutagenic in Escherichia coli, Journal of Bacteriology, Vol. 177, No. 10, Issue of May 1995, p. 2950–2952,1995.
- Bandaru, B., 2006, Making team perform at their peak potential, SNEC-PMI, Nov 2006, p.05.
Ben’s hobbies include reading, watching movies, playing tennis and Sudoku.
Director of Finance
Sophia joined the GGG team in 2011. As the Director of Finance, she is responsible for all GGG member companies' accounting and finance functions. Sophia manages the Accounting Department staff as well as day-to-day operations. She is responsible for establishing and maintaining all banking relationships, including financial reporting to banks and third-party investors. She provides leadership and strategy development for the company's long-term financial health and growth.
Before her appointment to Director of Finance in 2023, Sophia held positions of increasing responsibility in the Accounting and Finance Department, including Senior Accountant and Controller. Before joining GGG, Sophia brought over ten years of experience in the Accounting and Finance industries. She previously held positions as Senior Accountant at Freeze dba Central Mills Inc. and Cap Barbell as Accounting Manager. Sophia received her BS in Business Administration from Florida Atlantic University in Boca Raton, FL.
Chief Legal Officer
Susan joined the GBG team in 2011. As the Chief Legal Officer, Susan provides advice and leadership to the GBG family of companies to enhance its position in the fields of clinical diagnostics, drug discovery, product development, manufacturing, and distribution. In addition, Susan structures the transactions for mergers and acquisitions to assist GBG with its strategic growth initiatives in addition to managing a staff of attorneys and outside counsel to address challenges and litigation in the areas of corporate, regulatory, compliance, healthcare, intellectual property, contracts, and employment law.
Prior to her appointment to Chief Legal Officer in 2017, Susan held positions within GBG as Associate Regulatory Counsel 2011-2015, Associate General Counsel 2015-2016, and Deputy General Counsel 2016-2017.
Susan brought twenty five years of Legal experience to the GBG Team through her previous position State of New Jersey Officer of the Attorney General where she served as the Deputy Attorney General.
Susan received her BA & BS in Arts and Science from Pennsylvania State University in State College, PA. She earned her Juris Doctor from Widener University School of Law in Wilmington, DE.
Susan was proud recipient of many awards during her time in the Office of the Attorney General Awards including Excellence in Management 2009, Excellence in Investigations 2009, and Excellence in Trial Litigation 2008. Susan was also awarded with a 2014 Galaxy Award at GBG.
During her free time, Susan enjoys running, cycling, swimming, and movies. She is a Share the Music volunteer and Therapy Dog International volunteer.
Stephanie Berry, SHRM
Chief Human Resources Officer
Human Resources Department
Stephanie joined the GBG team in 2016 as the Human Resources Manager. In 2017 she became the Director of Human Resources, a position she held until 2020 when she transitioned into her current role as Chief HR Officer. Stephanie provides leadership to the HR Team and oversees benefits and compensation, wellness programs, talent acquisition and employee retention, employee recognition programs, performance management, training and development, compliance, leave administration, employee relations and event planning. Stephanie has implemented various innovations to replace the current HRIS and revamp the benefits program to attract and retain top talent. She provides on-boarding and HR support for new acquisitions and leads Human Resources initiatives for GBG and all member companies.
Prior to GBG, Stephanie held positions in Human Resources at State of NJ - NJ Housing and Mortgage Finance Agency as an HR Generalist as well as Adelphi Group and BluePrint Research Group as HR Manager. Stephanie brought to the GBG team over 15 years of HR experience in the Pharmaceutical and Mortgage and Finance Industries.
Stephanie received her BS in Business Administration/Management from University of Reading. Stephanie holds a certificate as a Professional in Human Resource (PHR) from Villanova University in Villanova, PA, as well as a Society for Human Resource Management - Senior Professional in Human Resources (SPHR).
Stephanie is an active member of the Society for Human Resource Management (SHRM). She was the proud recipient of a Congressional Award presented by Congressman Chris Smith in recognition of her work in foster care.
Stephanie enjoys spending time with her husband and children and their many activities, traveling and giving back their community. Stephanie and her husband are advocates for children in foster care and have fostered over 25 children in their effort to adopt.
Stephanie S. Thompson, MLS (ASCP)
Chief Marketing Officer
Creative Services Department
Stephanie joined the GGG team in 1999. As the Chief Marketing Officer, she leads the Creative Services Department members, including the graphic design team. She is responsible for developing, implementing, and maintaining the marketing efforts and supportive collateral for new and existing product lines and services for all GGG Member companies across all lines of business.
Stephanie joined Medical Diagnostic Laboratories, L.L.C. (MDL) as a Laboratory Technician in 1999 and has since held various management positions of increasing responsibility. She developed the Quality Control Department and became the Quality Control Manager in 2000. As the division grew in scope and size, in 2004, Stephanie became the Director of Quality Assurance & Quality Control. In 2007, she transitioned into the role of Director of Marketing. Stephanie held a dual Directorship for ten years and served as the Director of Administration from 2005 – 2015. In 2021, Stephanie assumed her current role as Chief Marketing Officer.
Chief Information Officer
Boris joined the GBG team in 2017. As the Chief Information Officer he is responsible for the strategic planning, design, implementation, and overall alignment of all technology infrastructure with the organizational goals GBG and its member companies. Boris directs the effective delivery of networks, applications, and disaster recovery and processes. He oversees a team of technology engineers, architects, and developers while working closely with management, external vendors, and advisors. Boris identifies solutions to manage daily business activities more efficiently through technological improvements which increase productivity and reduce costs and downtime.
Prior to joining GBG, Boris brought with him twenty years of experience in the information technology industry. He previously held positions as technical lead senior solution advisor at Anthem BC/BS and team lead of application modernization at Gap Gemini America.
Boris received his BS in Information Technology at Kiev National Polytechnic University in Kiev, Ukraine.
Chief Laboratory Strategy Officer
Genesis Biotechnology Group
Kelly joined the GBG team in 2004. As the Chief Laboratory Strategy Officer, Kelly is responsible for Kelly is responsible for overseeing and managing Medical Diagnostic Laboratories' clinical laboratory Customer Service, Quality Assurance, Quality Control, and the Clinical Laboratory.
Kelly began her career with MDL as a Laboratory Technician in 2004. In 2005 she became a Clinical Validation Technician and transitioned into the role of Clinical Implementation/Validation Coordinator in 2007. In 2010 Kelly was promoted to Assistant Director of the QA & QC Department. She held this position until 2012, when she became Director of Quality Control. In 2017 Kelly was promoted to Vice President of Clinical Laboratory Operations, a position she held until transitioning into her current role.
Gary Schieven, Ph.D.
Chief Scientific Officer
Genesis Biotechnology Group
Dr. Schieven joined the GBG team in 2020. As Chief Scientific Officer, he leads clinical development efforts for GBG’s STING agonist for treatment of cancer. He provides leadership, oversight, and coordination for the development and management of drug discovery efforts for oncology, immuno-oncology, metabolic disease, and immune-related disorders. Gary began his career with Genesis Research & Development Institutes as Director of Clinical Development where he lead clinical development efforts for GBG’s STING agonist or treatment of cancer.
Gary brought over 30 years of experience in the Immunology & Oncology Research industry to the GBG Team. He previously held a position with Bristol-Myers Squibb, as an award winning Senior Research Fellow.
Gary is the author of 112 publications, 12 patents and patent applications, and 41 presentations at scientific meetings. He led drug discovery programs leading to one marketed drug, Sprycel, plus 7 compounds into clinical development, including BMS-986256 currently in Phase II trials for lupus and BMS-986301 currently in Phase I trials in immuno-oncology.
Gary received his BS in Chemistry from St. John Fisher College in Rochester, NY. He earned a Ph.D. in Biochemistry from University of California at Berkeley in Berkeley, CA.
In his free time, Gary enjoys photography, hiking, travel and gardening.
Grant Gallagher, Ph.D.
Grant joined GGG in 2006 and has performed several roles for the company over this time. He is currently leading the Oncoveda cancer research group, which is part of the Genesis Research and Development Institute, GRDI.
While working for GBG, Grant has been an inventor on 24 issued US patents, 10 peer-reviewed primary research papers and seven other publications. He has graduated four MS graduate students. Grant is a member of the core team that is bringing a drug candidate forward to Phase-1 clinical trial. In addition to his research work, Grant has developed and released a successful Pharmacogenomics test to our clinical sales force.
Joseph Nickels, Ph.D.
Institute of Metabolic Disorders
Dr. Nickels joined the GBG team in 2007. As the Managing Director of the Institute of Metabolic Disorders, he oversees all research efforts currently focused on the discovery and development of novel therapeutics, with a special focus on for the treatment of lipid-dependent fatty liver disease (NAFLD/NASH).
Dr. Nickels began his career with MDL in the Research & Development Department, Division of Pharmacogenomics as a Team Leader. In 2009 he transitioned into the role of Scientific Director of VENENUM Biodesign and then Director of Target Biology in 2010. In 2012, Dr. Nickels became the Managing Director of the Institute of Metabolic Disorders.
Prior to joining GBG, Dr. Nickels was a professor of Molecular Biology at Drexel University College of Medicine in Philadelphia, PA for ten years. He has continued his role in Academia in recent years at UMDNJ-School of Osteopathic Medicine in the Department of Molecular Biology and Rowan University School of Medicine in the Department of Molecular Biology.
Dr. Nickels received his BS in Biochemistry from Rider University in Lawrenceville, NJ. He earned his Ph.D. in Molecular Genetics and Microbiology at Rutgers University in New Brunswick, NJ. Dr. Nickels completed his post-doctoral fellowship in Genetics at Princeton University in Princeton, NJ.
Rachael Alcantara, Ph.D.
Rachael joined the GBG team in 2008. As Director of Immunoveda, Rachael provides leadership, oversight, and coordination for the development and management of drug discovery efforts for immune-oncology and for the treatment of immune-related disorders. Rachael is also the Chairperson of the Genesis Biotechnology Group Institutional Animal Care and Use Committee.
Rachael began her career with GBG as a Scientist for Humigen in 2008. In 2013, she became Humigen’s Team Leader. She then transitioned to Team Leader of Venenum in 2015. In 2020, Rachael was promoted to Senior Team Leader of Venenum until her promotion to Assistant Director of Immunoveda in 2020. She held this position until 2022 when she transitioned into her current role as Director of Immunoveda.
Rachael received her BS in Biological Science from Rutgers University in New Brunswick, NJ. She earned her Ph.D. in Biochemistry and Molecular Biology from The Rockefeller University in New York, NY.
Rachael conducted her post-doctoral studies at Columbia University in New York, NY where she was the recipient of a fellowship from The Leukemia and Lymphoma Society. Rachael is the co-author of eight publications and co-inventor on three issued patents.
Chiayu (Joyce) Huang, Ph.D.
Chief Scientific Officer, Chemistry
Genesis Drug Discovery and Development (GD3)
Dr. Huang joined the GBG team in 2010. As the Chief Scientific Officer of Chemistry, she oversees a team of medicinal chemists in the optimization of small molecule therapeutic compounds aimed at immuno-oncology targets, metabolic disorders, and infectious disease. She also guides the bioanalytical characterization of lead molecules through pharmacokinetic and Absorption, Distribution, Metabolism and Excretion (ADME) studies. In addition, Dr. Huang is responsible for the maintenance and growth of Venenum’s 5.7 million member compound collection for high-throughput screening.
Dr. Huang began her career with VENENUM Biodesign as a Chemistry Team Leader. In 2015 she was promoted to Assistant Director of Medicinal Chemistry a position she held until 2019 when she transitioned into the role of Director of Medicinal Chemistry.
Dr. Huang is a medicinal chemist with more than 20 years of experience in drug discovery which spans a variety of therapeutic areas including Metabolic Disease, Oncology, Respiratory, CNS, and Inflammatory Disease. She previously held positions with Pharmacopeia as a Research Scientist and Senior Group Leader as well as Ligand Pharmaceuticals as a Senior Research Investigator.
Dr. Huang received her BS in Chemistry from National Taiwan University in Taipei City, Taiwan. She earned a Ph.D. in Organic Chemistry at University of Texas at Austin in Austin, TX. Dr. Huang completed her post-doctoral fellowship in Organic Chemistry at Duke University in Durham, NC.
James Beasley, Ph.D.
Chief Scientific Officer, Biochemistry & Bioanalytical
Genesis Drug Discovery and Development (GD3)
Dr. Beasley joined the GBG team in 2011. As Venenum’s Director of Biology, he oversees a team of scientists that support the research efforts in GBG’s pre-clinical drug discovery programs in therapeutic areas such as metabolic disorders, oncology, and infectious disease. Dr. Beasley’s Discovery Biology team specializes in the development, optimization, and execution of assays in the ultra-high-throughput screening (uHTS) of Venenum’s 5.7 million member compound library. The team also develops and performs assays, including several ADME-Tox assays, necessary to profile the small molecule therapeutic compounds produced by medicinal chemistry. Dr. Beasley serves as a member of the GBG Executive Council.
Dr. Beasley began his career with VENENUM Biodesign as the Discovery Biology Team Leader. In 2014 he was promoted to his current position as Director of Discovery Biology.
Dr. Beasley brought 12 years of experience in the Drug Discovery industry. He previously held positions with Ligand Pharmaceuticals as a Senior Research Investigator, Pharmacopeia as a Senior Principal Scientist, and DGI Biotechnology as a Senior Scientist.
Dr. Beasley received his BS in Chemistry from University of Texas at Austin in Austin, TX. He earned his PhD. in Chemistry at University of North Carolina at Chapel Hill in Chapel Hill, NC. Dr. Beasley completed his post-doctoral fellowship at Princeton University in Princeton, NJ.
Michael Van Zandt, Ph.D.
Vice President, Chemistry
Genesis Drug Discovery and Development (GD3)
Michael joined the GBG team in 2020. As Vice President of Chemistry for Genesis Drug Discovery & Development (GD3), he provides leadership, oversight, and coordination for the development and management of new drug discovery platforms within GD3s Chemistry Division.
Michael was previously President & Chief Executive Officer of New England Drug Discovery Partners (NEDP). He is an accomplished synthetic organic and medicinal chemist with more than 20 years of experience in large and small pharmaceutical company environments. Before founding NEDP, he was a department head and project leader for The Institute for Pharmaceutical Discovery (IPD) and a medicinal chemist at Bayer's pharmaceutical division. Michael, an inventor on more than 30 issued patents and author of more than 20 publications in peer-reviewed journals, is a frequent reviewer for the Journal of Medicinal Chemistry and Bioorganic Medicinal Chemistry Letters.
Michael received his Ph.D. in Organic Chemistry with a minor in Biochemistry while working with Distinguished Professor Carl R. Johnson at Wayne State University.
Brenda Petronella, Ph.D.
Director of Biochemistry and Molecular Biology
Brenda joined the GBG team in 2015. As Director of Biochemistry and Molecular Biology for Genesis Drug Discovery & Development (GD3), Brenda is responsible for overseeing operations and the expansion of services at Ingenio Diagnostics. She coordinates biochemistry and molecular biology services within GD3 and leads the Biochemistry and Molecular Biology Center of Excellence. Brenda collaborates across GD3 to ensure seamless workflows for studies with multiple downstream readouts performed across different sites. As a stakeholder in GD3's Ocular Center of Excellence, Brenda contributes to the development of protein and gene expression biomarker panels for glaucoma and AMD disease models.
Brenda began her career with GBG as Team Leader of Venenum Biodesign in 2015 where she continues to support assay development and compound profiling for small molecule drug discovery projects in oncology and metabolic disease. In 2022, she was promoted to Director of Biochemistry and Molecular Biology for GD3.
Before joining GBG, Brenda previously held positions at OSI Pharmaceuticals as Research Scientist, Astellas Pharma as Sr. Research Scientist, and Enzo Life Sciences as Senior Scientist. Brenda is a Biochemist with 15 years of experience in Biochemical Assay Development and Molecular Biology.
Brenda received her BS in Chemistry from the University of North Carolina at Chapel Hill in Chapel Hill, NC. She received her Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania School of Medicine in Philadelphia, PA and completed her post-doctoral training at Albert Einstein College of Medicine in Bronx, NY. She is the co-author of several publications and a recipient of various awards and honors.
Judit joined the GGG team in 2022. As the Managing Director of BioBlocks KFT, she is responsible for the Hungarian operation from legal, finance, HR and general administration aspects. She supports Genesis colleagues in BioBlocks' integration procedure with her international- and life science field experience.
Judit brought over 25 years of experience in Finance Management. Before GGG, she held positions at Omixon Biocomputing Kft, AMRI Hungary Zrt. (former Curia), Teva Pharmaceuticals and KPMG Hungary.
Judit received a B.A. in Business Administration from Bloomfield College of Business Administration, Rishon Le-Zion, Israel and post-graduate diplomas in Financial Management from ACCA - Association of Charted Certified Accountants and Property Management from the University of Economics and the Technical University of Budapest.
Zoltán Dalicsek, Ph.D.
Zoltan joined the GGG team in 2023. As the Managing Director of Organochem, he is responsible for the Hungarian operation and provides leadership, oversight, and coordination for the development and management of new drug discovery platforms within Organochem. Zoltan brought over 12 years of experience in the Chemistry Industry and extensive experience in Chemistry Research. Before GBG, he held a position at H4Sep Ltd. Zoltan received a M.Sc. degree in chemical engineering from Faculty of Pharmaceutical Studies at Budapest University of Technology and Economics and Ph.D. from Eötvös Loránd University, Chemistry Doctoral School.
Madeline Farley, Ph.D.
Dr. Farley is the Managing Director of PharmOptima in Portage, Michigan. Dr. Farley has 15 years of experience in neuroscience research and preclinical contract work, emphasizing molecular biology, biochemistry, biophysics and disease modeling. Dr. Farley joined PharmOptima in 2021 as a Senior Scientist within the Biochemistry group. Apart from her role in Biochemistry, she has worked closely with the Vivarium to establish ocular disease models within the Ocular Center of Excellence. Before joining PharmOptima, Dr. Farley investigated injury signaling pathways underlying neurodegenerative disease and neuronal injury using transgenic mice and AAV-based gene delivery systems targeting neurons within the retina. Dr. Farley received her BS in Biochemistry, with a minor in Mathematics, from Centenary College of Louisiana. She earned her Ph.D. in Cellular and Molecular Neuroscience at The University of Texas Health Science Center in Houston, TX. She completed postdoctoral fellowships at both McGovern Medical School at UTHealth and Baylor College of Medicine. Dr. Farley has been a recipient of a vision sciences postdoctoral fellowship through the National Eye Institute and an individual NRSA predoctoral fellowship through the National Institute of Neurological Disorders and Stroke.
Vladimir Khazak, Ph.D.
Head of Oncology
Invivotek & NexusPharma
Dr. Vladimir Khazak is an experienced biologist with more than 20 years of working in multiple biopharmaceutical companies. He is the co-founder and Chief Scientific Officer of NexusPharma, heading biology research and development. He received an M.S. and Ph.D. from Chemical-Technical University, Moscow Institute for Genetics and Selection of Microorganisms, in Moscow, Russia. He completed his postdoctoral research at Fox Chase Cancer Center in Philadelphia, PA in the relationship between basic transcriptional apparatus and stress. Particular areas of expertise include genetics and molecular oncology with a particular emphasis on protein-protein interaction, gene regulation/expression and signal transduction.
Rukiye Nazan Eraslan, Ph.D.
Chief Scientific Officer
Disease Modeling division within Genesis Drug Discovery & Development (GD3)
Dr. Eraslan joined the GBG team in 2019. As the Chief Scientific Officer, she functions as a scientific thought-leader, provide deep domain area expertise to both internal and external stakeholders. She led the scientific negotiation and due-diligence as a first layer to deliver decisional statements and explain data driven scientific rationale in to business, Rukiye also provides program/project management and operational support for drug development programs/projects (DDPP) to maintain accurate plans and documentation. As the voice of company, regularly interact with leadership of other functional areas, board of directors and key external stakeholders, including investors, regulators, and scientific communities. She contribute to the evolution of corporate strategy and participate in corporate decision-making.
Dr. Eraslan brings over 20 years of experience in Immunology and Oncology within multi-disciplinary matrix teams comprised of colleagues from various groups including Discovery, Safety, Clinical and Regulatory to develop and deliver biomarker strategies and potential combination therapies for immuno-oncology and autoimmune diseases assets. She is highly experienced in launching and leading new research programs and new research organizations with a growth mindset and a deep commitment to innovation. She previously held positions at Xenogen/Caliper Life Sciences as Team Leader Immunology & Inflammation, Taconic, Inc., as Team Leader/Principal Scientist Immunology & Inflammation, Team Leader at Invivotek and Bristol Meyers Squibb as a Principal Scientist in Immuno-Science and Oncology.
Dr. Eraslan received a M.S. in Molecular Biology from Illinois Institute of Technology in Chicago, IL. She earned a Ph.D. in Immunology at University of Illinois in Chicago, IL. Dr. Eraslan completed her post-doctoral fellowship in Immunology at Northwestern University Medical School in Chicago, IL.
Fariba Chalajour, MD, MBA
Comparative Biosciences, Inc.
Dr. Chalajour joined the GBG team in 2020. As the Managing Director of Comparative Biosciences, Inc, a GLP preclinical CRO based in California, she manages the company’s operations, ensures high-quality preclinical studies, and provides strategic leadership in animal study design and to the histopathology team. By combining her business acumen with her 20 years of experience in experimental medicine and translational research, she fosters collaborative relationships with clients and stakeholders to successfully meet their project needs and regulatory requirements.
Prior to her current role, Dr. Chalajour held the position of VP of Preclinical Histopathology at Comparative Biosciences, Inc. In this role, she oversaw scientific and operational activities related to histopathology projects and formulated business objectives. She also managed the sales and marketing activities and developed client relationship management strategies. She was promoted to Managing Director in 2022.
Dr. Chalajour earned her medical degree from Azad University Medical School in Tehran, Iran. Her residency training was focused on cardiovascular surgery at University Heart and Vascular Center in Hamburg, Germany. Following this, she completed her research fellowship in cardiothoracic surgery at Stanford University Medical Center. Throughout her career, Dr. Chalajour has contributed to scientific literature and presented her research findings at conferences. She has been involved in multiple peer-reviewed articles and worked as a consultant to various pharmaceutical and medical device companies.
STATKING Clinical Services
As Vice President, Sarah works with SCS directors to determine company priorities and coordinate Corporate Core Services Divisions, including Information Technology, Human Resources, and other GD3 member companies. Sarah joined SCS in 2008 and since that time has held various positions of increasing responsibility, including Data Manager, Statistical Programmer, Section Head for Statistical Programming, and Director of Statistical Programming and Data Management. Her specific areas of expertise are biostatistics, SAS programming, CDISC standards and EDC software programming. She is an accomplished SAS programmer who has written SOPs governing auditable SAS programming processes. She received her MS in Public Health in Biostatistics at the University of South Carolina in Columbia, South Carolina.
John Sampalis, B.Sc., B.A.(Hon), M.Sc., Ph.D., F.A.C.E, F.A.H.A
Chief Executive Officer and Chief Scientific Officer
JSS Medical Research
Dr. Sampalis joined the GBG team in 2023. As CEO and Chief Scientific Officer of JSS Medical Research. He is a tenured professor of Surgery and Epidemiology & Biostatistics of McGill University, the University of Montreal and Laval University. Throughout his career he has received numerous scholarships from provincial and federal funding agencies including the Medical Research Council of Canada, the National Health Development Program and the Fonds de la recherche en santé du Quebec. With over 175 peer-reviewed publications in high ranking journals and more than seven million dollars in research funding, Dr. Sampalis is recognized as one of the leading clinical epidemiologists in the world, and one of the top trauma researchers in Canada.
Possessing extensive expertise in health services research, clinical trials and the evaluation of medical technology, Dr. Sampalis also offers services as a Research and Epidemiological Consultant for numerous pharmaceutical companies, hospitals and government organizations and agencies.
Dr. Sampalis currently holds a Medical Scientist Salary Award from the Medical Research Council of Canada and has previously received numerous prestigious scholarships and awards including the National Health Research and Development Scholar from Health Canada. In addition, he participates as a reviewer for over five leading peer-reviewed journals and as a committee member for provincial and federal funding agencies.
As Chief Scientific Officer at JSS Medical Research, he continues to contribute to scientific aspects of the clinical trials in collaboration with the VP, Scientific Affairs team to ensure sound scientific expertise and that data quality and integrity are maintained.
Louise Bussieres, CPA
President and CFO
JSS Medical Research
Throughout Ms. Bussieres' career, she has been involved in strategic planning, financing, accounting, mergers and acquisitions, treasury and contract negotiations in the pharmaceutical research and development field. From 1981 to 1990, she held several positions within the auditing group of KPMG, an international accounting and consulting firm. In 1990, she joined the Institute Armand-Frappier, an academic research institute, as Chief Accountant and was responsible for the implementation of a new accounting information system in support of the research effort. In 1995, she was Associate Director of the Center for Experimental Biology (the preclinical research division of the Institute). Operational man-management, general administration as well as financial responsibility and control were features of this position. As a company founder, Louise joined LAB International in May 1999 as Vice President, Finance. As the Chief Financial Officer (“CFO”) of the company, she held financial responsibility as the company grew from $3m in revenue in 1999 to over $10m in 2002 when she was pivotal in taking the company public through a Reverse Take-Over mechanism on the Toronto Stock Exchange. In 2002 and 2004, she managed financial due diligence for the acquisition of facilities in Hungary, Denmark and Finland and also founded a new, wholly-owned subsidiary company in California. In 2006, she was central to the secondary Initial Public Offering transaction of LAB (now at $45m revenue) and continued as Vice President Finance with full M&A and other public reporting responsibilities. In 2010, she moved to Singapore and founded L2 Consulting with business interests (primarily business planning and financial management as CFO) for a number of biotech companies in Asia, US and Canada. She returned to Canada in 2014 where she continued operations of L2 in America. In October 2017, she joined JSS Medical Research Inc. as President and CFO.
President of Sales & Business Development
Genesis Clinical Diagnostics
Bridgette joined the GBG team in 2004. As the Vice President of Sales for Medical Diagnostic Laboratories, Bridgette leads a highly functioning national sales force and provides the tools, policies, and processes needed for their ongoing success. She develops and cultivates strategic partnerships, business development strategies, and alliances to drive continuous revenue growth and market share. For over 15 years, Bridgette has been a well-known and awarded sales producer in the laboratory industry and has held several leadership positions of increasing responsibility.
Bridgette was born and raised in Ponchatoula, Louisiana. She earned a state scholarship and was later relocated by the United States Air Force to New Jersey, where she found Medical Diagnostic Laboratories. After spending over a decade establishing her sales career across multiple states and regions, Bridgette now resides back in Ponchatoula with her husband and two daughters.
Director of Quality Assurance
Medical Diagnostic Laboratories
Kim joined the GBG team in 1998. As the Director of Quality Assurance, Kim is responsible for maintaining federal and state licensing for the Clinical Laboratory as well as all regulatory compliance.
Kim joined MDL as a Laboratory Technician in 1998 and has since held various management positions. She was manager of the Clinical Laboratory until 2007 when she became Director of the Quality Assurance (QA) & Quality Control (QC) Department. She held this position until 2012 when she became Director of Quality Assurance, enabling her to focus on licensing and regulatory compliance issues.
Kim received her BS in Biology from Temple University in Philadelphia, PA.
Director of Operations
Medical Diagnostic Laboratories
Bill joined the GBG team in 2009. As the Director of Operations, he oversees the Logistics, FST, Shipping & Receiving, Warehouse, Fleet and Operations divisions and personnel. Bill is responsible for ensuring the efficient and timely transport of all specimens to the laboratory. He continuously works to develop new processes and procedures to increase efficiencies and drive down ever growing operational costs. He works to improve the business processes for the department through analysis and collaboration with other departments.
Bill joined MDL as the Operations Manager of Sherute, LLC., a position he held until 2011 when he became Assistant Director of Operations. In 2016, Bill transitioned into his current role as Director of Operations of MDL.
Bill brought more than twenty years of experience in Operations and Facilities Management to the GBG team. He proudly served his country in the US Navy as an Operations Specialist 2nd Class Petty Officer with a concentration in Combat Information Center Operations. He previously held positions at California Closet Company as a Foreman with a concentration in cabinetry and at Congoleum Corporation in Administrative Services as a Facilities Manager.
Bill received a Certificate of Completion from the US Navy Nuclear Power "A" School and has been working towards a BA in Business Management from Rider University College of Continuing Studies.
Vice President of Lab Operations
Medical Diagnostic Laboratories
Brian joined the GBG team in July 2000. As the Director of Operations for Bioplast, Brian is responsible for the overall operation and administration of an ISO 9001 certified injection molding manufacturing company, specializing in laboratory plastic ware and disposables. He is responsible for the recruitment and employment needs for the production and maintenance staff, selection of primary and auxiliary equipment, and leading the development and implementation of the QMS for ISO 9001. He is responsible for tooling, equipment and automation fabrication timelines, costs, and delivery schedules.
Brian initially joined MDL as a Laboratory Technician in 2000. In 2002 he became Third Shift Coordinator, a position he held until 2009 when he transitioned into his current role at Bioplast Manufacturing.
Brian received his BA in Biology from Rutgers University in New Brunswick, NJ.
Director of Lab Operations
Medical Diagnostic Laboratories
Bhavina joined the GBG team in 2010. As Director of Laboratory Operations, Bhavina is responsible for overseeing and managing all aspects of Medical Diagnostic Laboratories’ clinical laboratory operations on a day-to-day basis including compliance with all applicable regulations. Bhavina is responsible for managing recruitment and employment needs of clinical laboratory personnel, and supervises training and development of all laboratory personnel. Bhavina also oversees all quality control issues pertaining to the clinical lab.
Bhavina began her career with MDL as a Laboratory Technician in 2010. In 2011, she became a Clinical Validation Technician. She then transitioned into the role of Shift Coordinator in 2013. In 2018, Bhavina was promoted to Assistant Laboratory Manager. She held this position until 2020, when she became Laboratory Manager. In 2022, Bhavina was promoted to her current position of Director of Laboratory Operations.
Bhavina received her BS in Biotechnology from Kean University in Union, NJ.
Director of Lab Operations – Technology
Medical Diagnostic Laboratories
Tyler joined the GBG team in 2017. As Director of Laboratory Operations, Tyler oversees the development, validation, and assists with the implementation of new automated processes. He directs the daily workflow within each area of the laboratory and delegates additional resources when needed to accommodate specimen volume and flow. Tyler troubleshoots escalated problems within the laboratory workflow and works towards a corrective action.
Tyler began his career with MDL as a Clinical Laboratory Technician in January 2017. In July 2017, he became 1st Shift Coordinator of the Clinical Laboratory. In 2019, Tyler was promoted to the role of Junior Project Manager of Laboratory Operations. He held this position until 2022, when he was promoted to his current role of Director of Laboratory Operations.
Tyler received his BS in Physics at Rowan University in Glassboro, NJ.
Director of Quality Control and Lab Services
Medical Diagnostic Laboratories
Rachel joined the GBG team in 2015. As Director of Quality Control and Laboratory Services, Rachel is responsible for the daily operations of the Quality Control department. Rachel reviews the daily pending list, coordinates internal proficiency samples, and monitors technician performance. Rachel’s ongoing projects include preparing instrument validations and compliance monitoring.
Rachel began her career with MDL as a Lab Technician in 2015. In 2017, she was promoted to Next Generation Sequencing Coordinator. She held this position until 2018 when she became Assistant Laboratory Manager. In 2020, she was promoted to Clinical Laboratory Manager. She held this position until 2022, when she was promoted to her current role as Director of Quality Control and Laboratory Services.
Rachel received her B.S. in Biology at Stockton University in Galloway, NJ.
Vice President of Sales – East Division
Medical Diagnostic Laboratories
Alison joined the GBG team in 2012. As the Vice President of Sales - Eastern Division for Medical Diagnostic Laboratories, Alison leads the sales team in the Eastern Division. She is responsible for developing business strategies to drive revenue growth and building strategic partnerships in the territory while fostering a strong relationship with current partnerships and clients.
Alison began her career with MDL as a Senior Sales Executive. She held several leadership positions of increasing responsibility within the MDL Sales Team, including District Sales Manager – Pennsylvania, Sector Sales Manager – Northeast Region, Integration Manager, and Sales Director before transitioning into her current role in 2022. Prior to MDL, Alison held positions as a Medical Technician at Bi-county Urology, Client Service Coordinator at Sunrise Medical Laboratories, and Director of Operations at US Cannalytics.
Alison received a Medical Assistant Certificate in Clinical Laboratory Science/Medical Technology from Sanford-Brown Institute in White Plains, New York City; an AS in Business Administration and Management from Nassau Community College in Uniondale, New York; and a BS in Wildlife, Fish, and Wildlands Science and Management from Oregon State University in Corvallis, Oregon.
Marie Barry, MLS(ASCP)cm
Vice President of Sales - West Division
Medical Diagnostic Laboratories
Marie joined the GBG team in 2017. As the Vice President of Sales - West Division for Medical Diagnostic Laboratories, Marie leads the sales team in the Western Division. She is responsible for developing business strategies to drive revenue growth and building strategic partnerships to expand the client base in the West Division. While fostering a strong relationship with current partnerships and clients, While working on expanding MDL's footprint in the West Division of the US, Marie also oversees the education of existing and new clients on MDL's clinical advantages and cutting-edge testing.
Marie began her career with MDL as a Senior Sales Executive. She held several leadership positions of increasing responsibility within the MDL Sales Team, including District Sales Manager, a position she held for three years before transitioning into her current role. Before MDL, Marie held positions as a Medical Laboratory Scientist at CHI Lakeside Hospital Laboratory.
Marie received a BS in Biology from Concordia University and BS in Clinical Laboratory Science at the University of Nebraska Medical Center in Lincoln, Nebraska.
Vice President of Sales - Central Division
Medical Diagnostic Laboratories
Jessica joined the GBG team in 2018. As the Vice President of Sales - Central Division for Medical Diagnostic Laboratories, Jessica leads the sales team in the Central Division. She is responsible for developing business strategies to drive revenue growth and building strategic partnerships in the territory while fostering a strong relationship with current partnerships and clients.
Jessica began her career with MDL as a Senior Sales Executive. She held several leadership positions of increasing responsibility within the MDL Sales Team including, District Manager, and Sector Manager before transitioning into her current role. Jessica received a BA in Secondary Education-Mathematics from Concordia University in Mequon, Wisconsin.
Jon C. Sniffen, MDxt (AAB)
Director of Laboratory Operations
Jon joined the GBG team in 2002. As the Director of Laboratory Operations of SunPath-MDL, he is responsible for overseeing and managing all aspects of clinical laboratory operations including recruitment and employment needs of all laboratory personnel. Jon oversees the training and development of all laboratory technical personnel. He monitors compliance with all applicable regulations and provides day-to-day on-site supervision of specimen processing, test performance, and analysis.
Jon began his career with MDL as a Laboratory Technician in 2002 and has since held various positions of increasing responsibility including Assistant Coordinator, Second Shift Coordinator, Laboratory Technology Manager. In 2017 Jon was promoted to his current position of Director of Laboratory Operations for SunPath-MDL.
Jon received his BA in Molecular Biology from Rutgers University in New Brunswick, NJ.
Deborah Giusto, MD
Pathologist and Managing Director
Dr. Giusto is board-certified in Anatomic and Clinical Pathology by the American Board of Pathology. She completed Pharmacy Curriculum at Lewis University in Romeoville, Illinois. She received both a Doctor of Pharmacy and Doctor of Medicine with honors from the University of Illinois in Chicago, Illinois. Dr. Giusto has published several abstracts and publications in peer-reviewed medical journals and contributed to a book chapter in a recently published authoritative textbook of liver pathology. Before earning her medical degree, Dr. Giusto was a pharmacist for ten years, working in an underserved area on the West Side of Chicago.